Syros Pharmaceuticals Implements Genedata Profiler to Accelerate Therapeutic Development for Genomically Targeted Patient Populations
Summary
“To accelerate the development of medicines for genomically targeted patient populations, a computational platform is critical to support our translational and clinical research strategy,” said Nancy Simonian, M.D., Chief Executive Officer of Syros. Beyond software, Genedata’s scientific domain expertise, and experience of over 25 years in the biopharma business ensures quick adoption of the platform in the company’s infrastructure, accelerating digital transformation within the translational and clinical research programs. “We are excited to collaborate with Syros Pharmaceuticals, a leader in the development of small molecules medicines changing the expression of genes, to help bring targeted treatments faster to patients with cancer and monogenic diseases,” said Othmar Pfannes, Ph.D., CEO of Genedata. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches.
Classifications
AskAI Classifications
LabelsLinked Companies
